KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Change in Cash (2017 - 2025)

Historic Change in Cash for Bionano Genomics (BNGO) over the last 9 years, with Q3 2025 value amounting to -$497000.0.

  • Bionano Genomics' Change in Cash rose 9606.77% to -$497000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.1 million, marking a year-over-year increase of 7622.02%. This contributed to the annual value of -$8.8 million for FY2024, which is 16825.08% down from last year.
  • Bionano Genomics' Change in Cash amounted to -$497000.0 in Q3 2025, which was up 9606.77% from -$63000.0 recorded in Q2 2025.
  • Bionano Genomics' 5-year Change in Cash high stood at $323.6 million for Q1 2021, and its period low was -$191.8 million during Q3 2021.
  • Over the past 5 years, Bionano Genomics' median Change in Cash value was -$523000.0 (recorded in 2022), while the average stood at -$1.9 million.
  • The largest annual percentage gain for Bionano Genomics' Change in Cash in the last 5 years was 363014.07% (2021), contrasted with its biggest fall of 1156551.11% (2021).
  • Quarter analysis of 5 years shows Bionano Genomics' Change in Cash stood at -$116.2 million in 2021, then skyrocketed by 80.48% to -$22.7 million in 2022, then grew by 26.7% to -$16.6 million in 2023, then soared by 102.28% to $379000.0 in 2024, then plummeted by 231.13% to -$497000.0 in 2025.
  • Its Change in Cash was -$497000.0 in Q3 2025, compared to -$63000.0 in Q2 2025 and -$5.9 million in Q1 2025.